RIDOC BASED MAT FOR OPIATE USE DISORDERS

Slides:



Advertisements
Similar presentations
Implementing routine hepatitis B vaccination at the Rhode Island Department of Corrections (RIDOC) Women’s Division Beth Schwartzapfel Jennifer Clarke.
Advertisements

COMPASS: COMMUNITY PARTNERSHIPS AND SOCIAL SERVICES FOR PEOPLE LIVING WITH HIV LEAVING THE JAIL SETTING Emily Patry, BS The Miriam Hospital, Providence,
Massachusetts Department of Correction Bridgewater State Hospital Luis S. Spencer, Commissioner.
ATLAS PROGRAM: HIV TESTING AND LINKAGE IN THE CUYAHOGA COUNTY CORRECTIONS CENTER Rachel Ciomcia, LISW-Project Coordinator Jenice Contreras, Director of.
Opioid Safety Phillip Coffin, MD, MIA Director of Substance Use Research San Francisco Dept. of Public Health Assistant Clinical Professor University of.
Melissa Klein 11/6/ Healthcare for the Homeless Project (HCHP) 1996 HCHP becomes grantee to run community health centers and becomes a FQHC.
ENROLLING JUSTICE INVOLVED POPULATIONS: POLICY IMPLICATIONS LINDSAY NELSON KENTUCKY PRIMARY CARE ASSOCIATION.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Substance Abuse Treatment and Corrections
Management of Hepatitis C: An Unprecedented Challenge for Corrections Brad Livingston Executive Director, Texas Department of Criminal Justice Lannette.
Psychopharmacotherapy in Correctional Institutions Robert P. Schwartz, M.D. Friends Research Institute Supported by NIDA R01 DA (PI: Kinlock)
The Rhode Island Experience Ellen Evans Alexander Assistant Director RI Department of Corrections.
Theodore M. Hammett, Ph.D. Sofia Kennedy, M.P.H. Drug Abuse and Risky Behaviors: The Evolving Dynamics of HIV/AIDS NIH-Bethesda, MD May 9, 2007 HIV/AIDS.
Prisoner Medicaid Eligibility Incarcerated Populations, the Affordable Care Act, and the Challenge of 2014 Brad Brockmann, JD, MDiv, Executive Director,
HIV Testing Strategies and Linkage to Care for Criminal Justice Populations Timothy P. Flanigan, MD Professor of Medicine Brown Medical School.
BUREAU OF GOVERNMENTAL RESEARCH Behind Bars: Orleans Parish Prison and the Inmate Population New Orleans does not have a Prison New Orleans has a Jail.
SARAH M. BAGLEY, MD ASSISTANT PROFESSOR OF MEDICINE AND PEDIATRICS BOSTON UNIVERSITY SCHOOL OF MEDICINE AMERSA ANNUAL CONFERENCE NOVEMBER 5, 2015 Overdose.
DMH Continuing Care Admissions, Referrals & Utilization Behavioral Health Data Task Force December 18,
Buprenorphine {Suboxone®, Subutex®}
Barnstable County Sheriff’s Office’s Educating Inmates on Medication Assisted Recovery _________________ Roger Allen LMHC Director of Inmate Services Jessica.
Justice Health Justice Health and Opioid Substitution The Justice Response Presenters:Larissa Strong, Director Justice Health Scott Drummond, Senior Policy.
Medication Assisted Treatment
Correctional Mental Health for Non-Mental Health Professionals
Health Reform: Understanding and Navigating the
Copyright 2011 Curriculum Technology, LLC. All Rights Reserved.
Integrating HIV, TB and Addiction Treatment in Malaysian Prisons
Opioid Use Disorder and pregnancy seminar
Western Node Collaborative
Center of Excellence Kate Henry LCSW, CCDPD Stacey Burroughs, LPC, CAADC Behavioral Health Service Line May 15th 2017.
Integrating Care Through Partnerships – Missouri’s Experience
Health Reform: Understanding and Navigating the
Santa Barbara County Re-Alignment Strategy Study
Medication-Assisted Therapy at Coleman Profession Services
Caldwell County Narcotic Initiative
McLean Hospital Division of Alcohol and Drug Abuse
Emily Patry, BS The Miriam Hospital, Providence, RI
Opioids – A Pharmaceutical Perspective on Prescription Drugs
Summary Report: Management of Hepatitis C in Prisons
MAT IN PRISON: ON THE INSIDE
David Loveland, Ph.D. Community Care
THR Behavioral Health Service Line
Pre-trial Medication Assisted Treatment
Department of Corrections
Medication Assisted Treatment
Medication-Assisted Treatment 101: Breaking the Stigma
Medicaid Pre-Release Enrollment Program.
Hepatitis B vaccination of prisoners
Medication Assisted Treatment Programs in
Bidirectional Association Between Homelessness and Incarceration Among Veterans Participating in HUD-VASH Dennis Culhane, PhD.
Opioids in Butte County
Maintenance Treatment
Caring for the Expanding Patient Population:  Treating the Recently Incarcerated
Department of Corrections
buprenorphine-naloxone
Professor Jack Lambert
Medication Assisted Treatment: Changing the Trajectory of the Opioid Epidemic
Vision Transformative collaboration that fosters resilient self-sustaining Recovery Communities. Mission To develop and sustain measurable solutions that.
The relationship between incarceration and opioid addiction treatment
Are you sick and tired of being sick and tired?
Alcohol, Other Drugs, and Health: Current Evidence
Opioid Use Disorders: Impact on HIV
The Judicial Branch’s Response to the Opioid Crisis
Strategic Initiatives to Address Opioid Overdose & Addiction
Pilot Peer Mentoring Program at WSPF
Premiere Continuing Education
Medication Assisted Treatment of Opioid Use Disorder
Ann Cox, DNP, FNP-BC, PMHNP-BC
Tapering and Discontinuing Chronic Opioid Therapy
Department of Corrections FY16 Budget Request
Treat Opioid USE DISORDER like the chronic disease it is
Presentation transcript:

RIDOC BASED MAT FOR OPIATE USE DISORDERS Jennifer Clarke MD MPH FACP Medical Program Director RI DOC Associate Professor of Medicine Brown University

Financial Disclosures I have no financial disclosures

Opioid Deaths by person‐years since being released from a MA state prison. 2013‐2014 (121 deaths) Deaths per 1000 person‐years We can see that most deaths occur within the first month of release. Everyone else (non‐former state prison inmates): 15.4 (2071 deaths) Courtesy of Dr. Thomas Lincoln

Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomized, open-label trial. JD Rich et al. Lancet 2015. Probability of clinic attendance (%) Figure 2. Probability of attending a methadone clinic in (A) intention-to-treat and (B) as-treated populations at 1 month follow-up after release from incarceration.

Buprenorphine begun before or after release RIDOC. Zaller et al. J Subst Ab Treat 2013

RIDOC Overview Unified Correctional system 6 Facilities Average daily census 3,100 FY 2015 12, 650 commitments Large percentage of <1yr sentence Monthly awaiting trial census 600-700 Intake HSC Maximum Medium The RIDOC is a Unified correctional system consisting of 6 inmate housing facilities that house an average of 3,100 inmates a/t, sentenced, & community corrections all fall in RIDOC jurisdiction 2 awaiting trial buildings that had 14, 928 commitments in the FY 2015 On Average the monthly a/t population census runs between 6 & 700, the average LOS is 23 days with the median LOS being 3 days 73% male and 89% female inmates were sentenced to 1yr or less in FY 2015 The DOC health services unit is a State run healthcare service under the direction of the Medical Programs Director. The services provided include medical, mental health, dental, &health education. Additionally the state contracts with numerous community providers for specialty medical services Women’s Minimum http://www.doc.ri.gov/administration/planning/docs/FY15%20Population%20Report.pdf

RI DOC MAT History Methadone maintenance only for pregnant women Methadone withdrawal for the past 20 years Origin Nov 2015 the Task Force developed a strategic plan for the Governor The long term goal is “To reduce opioid overdose deaths by one- third within three years.” Program Goals: MAT if appropriate for 3 populations: Continue MAT for 12 months Initiate MAT upon commitment Initiate MAT prior to release

MAT Medication Type METHADONE BUPRENORPHINE NALTREXONE Average daily dose METHADONE BUPRENORPHINE NALTREXONE

Released to Community per Month CODAC onsite should eliminate those discharged before receiving MAT

MAT After ReleaseN=1339 releases  Disposition MEDICATION Total METHADONE NALTREXONE BUPRENORPHINE Continued from community 481 1 258 740 (55%) Induction at commitment 271 8 216 495 (37%) Pre-release induction 35 12 57 104 (8%) 787 (59%) 21 (2%) 531 (39%) 1339 Dates 10/2016 – 9/2017

MAT Community Follow-up  MAT after Release Disposition Total Continued Induction Pre-release No 46 (6.2%) 318 (64.2%) 48 (46.2%) 412 (30.8%) Yes 694 (93.8%) 177 (35.8%) 56 (53.8%) 927 (69.2%) 740 495 104 1339 N=74 (5.5%) additional releases received MAT at CODAC post release but were not in BHOLD or PMP. Missing people in treatment out of state Naltrexone poorly documented

Mortality due to opioid overdose in RI January-June 2016 vs. January-June 2017 Compared opioid overdose mortality general population to individuals with an incarceration in the 12 months prior to death

Relative Risk Reduction= 61% Decedents: Recent Incarceration First 6 Months 2016 First 6 Months 2017 Decrease YES 26 9 17 (65%) NO 153 148 5 (3%) TOTAL 179 157 22 (12%) Relative Risk Reduction= 61% ((9/157)-(26/179))/(26/179)

Challenges / RI Advantages Community Vendor Inmates become patients of the community provider upon enrollment Community vendor has 7 sites throughout the state so seamless community transition Unified System Unless a patient is transferred out of state we don’t need to worry about MAT being stopped if transferred to another facility that does not offer MAT One Campus/ Small state Continuity of care through out incarceration No one is more than 15 miles from an MAT provider in the community

QUESTIONS? Jennifer.Clarke@DOC.RI.GOV